Immunotherapy, a rapidly evolving field in oncology, offers a novel approach to cancer treatment by harnessing the body's immune system to fight cancer cells. This article aims to provide physicians with a comprehensive understanding of the principles underlying this innovative treatment modality.
Immunotherapy operates on the premise that the immune system, when properly stimulated, can identify and destroy cancer cells. This is achieved through various strategies, including immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines. These therapies either enhance the immune response or counteract the mechanisms by which cancer cells evade immune detection.
Checkpoint inhibitors work by blocking proteins that prevent immune cells from attacking cancer cells. CAR T-cell therapy, on the other hand, involves modifying a patient's T cells to express receptors that target specific cancer antigens. Cancer vaccines, like the HPV and Hepatitis B vaccines, prevent virus-induced cancers by stimulating an immune response against viral antigens.
Immunotherapy has shown efficacy in various cancers, including melanoma, lung, and kidney cancers. However, its success is not universal, and some patients may not respond due to factors such as genetic mutations or the tumor microenvironment. Additionally, immunotherapies can cause severe immune-related adverse events, necessitating careful patient monitoring.
Research is underway to broaden the applicability of immunotherapy and improve patient outcomes. This includes combination therapies, biomarker identification for patient selection, and strategies to mitigate adverse events. The development of neoantigen vaccines, which target unique mutations in a patient's tumor, also holds promise.
Immunotherapy represents a paradigm shift in cancer treatment, offering potential for durable responses in various cancers. Understanding its principles and nuances is crucial for physicians to incorporate this treatment modality into their practice and to navigate its challenges. Continued research and innovation are expected to further refine and expand the use of immunotherapy in the future.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation